Current Allergy and Asthma Reports

, Volume 8, Issue 6, pp 484–492 | Cite as

New types of immunotherapy in children

  • Noel Rodríguez-Pérez
  • Martin Penagos
  • Jay M. Portnoy
Article

Abstract

Injection immunotherapy has been shown to be particularly beneficial in treating allergic rhinitis, mild to moderate asthma, and anaphylaxis caused by bee and wasp venom. It also produces a long-term, antigen-specific, protective immune effect and is the only treatment that offers the possibility of reducing the risk of asthma development in children with allergic rhinitis. Nonetheless, the potentially severe side effects associated with this form of immunotherapy limit its widespread use. Diverse preparations are being developed to increase its safety and improve its efficacy. These include alternative routes of administration, particularly the sublingual route; use of novel adjuvants, such as CpG oligonucleotides and mycobacterial vaccines; and other approaches, such as peptide immunotherapy, recombinant allergens, DNA vaccination, and combined therapy. Some of these immunotherapy forms have been evaluated in children.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Abramson MJ, Puy RM, Weiner JM: Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003, 4:CD001186.Google Scholar
  2. 2.
    Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 1:CD001936.Google Scholar
  3. 3.
    Durham SR: Tradition and innovation: finding the right balance. J Allergy Clin Immunol 2007, 119:792–795.PubMedCrossRefGoogle Scholar
  4. 4.
    Larché M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6:761–771.PubMedCrossRefGoogle Scholar
  5. 5.
    Valenta R, Niederberger V: Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007, 119:826–830.PubMedCrossRefGoogle Scholar
  6. 6.
    Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002, 2:446–453.PubMedGoogle Scholar
  7. 7.
    Scadding GK, Brostoff J: Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986, 16:483–491.PubMedCrossRefGoogle Scholar
  8. 8.
    Passalacqua G, Guerra L, Pasquali M, Canonica GW: Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets 2006, 5:43–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Bousquet J, Van Cauwenberge P: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108(5 Suppl):S146–S150.Google Scholar
  10. 10.
    Di Rienzo V, Minelli M, Musarra A, et al.: Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005, 35:560–564.PubMedCrossRefGoogle Scholar
  11. 11.
    Khinchi MS, Poulsen LK, Carat F, et al.: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004, 59:45–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Quirino T, Iemoli E, Siciliani E, et al.: Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996, 26:1253–1261.PubMedCrossRefGoogle Scholar
  13. 13.
    Frew AJ: Sublingual immunotherapy. N Engl J Med 2008, 358:2259–2264.PubMedCrossRefGoogle Scholar
  14. 14.
    Dahl R, Kapp A, Colombo G, et al.: Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008, 121:512–518.PubMedCrossRefGoogle Scholar
  15. 15.
    Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60:4–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Penagos M, Compalati E, Tarantini F, et al.: Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006, 97:141–148.PubMedCrossRefGoogle Scholar
  17. 17.
    Penagos M, Passalacqua G, Compalati E, et al.: Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008, 133:599–609.PubMedCrossRefGoogle Scholar
  18. 18.
    Valovirta E, Jacobsen L, Ljorring C, et al.: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006, 61:1177–1183.PubMedCrossRefGoogle Scholar
  19. 19.
    Lue KH, Lin YH, Sun HL, et al.: Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006, 17:408–415.PubMedCrossRefGoogle Scholar
  20. 20.
    Röder E, Berger MY, Hop WC, et al.: Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007, 119:892–898.PubMedCrossRefGoogle Scholar
  21. 21.
    Fornix Biosciences: Study confirms effect and safety of sublingual immunotherapy. Fornix Biosciences website. Available at http://www.fornix.nl. Accessed August 29, 2008.
  22. 22.
    Cao LF, Lu Q, Gu HL, et al.: Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides farinae drops [in Chinese]. Zhonghua Er Ke Za Zhi 2007, 45:736–741.PubMedGoogle Scholar
  23. 23.
    Bernardini R, Campodonico P, Burastero S, et al.: Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006, 22:1515–1522.PubMedCrossRefGoogle Scholar
  24. 24.
    Pajno GB, Caminiti L, Vita D, et al.: Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007, 120:164–170.PubMedCrossRefGoogle Scholar
  25. 25.
    Fiocchi A, Pajno G, La Grutta S, et al.: Safety of sublingualswallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005, 95:254–258.PubMedGoogle Scholar
  26. 26.
    Rodriguez-Perez N, Ambriz-Moreno MJ, Canonica GW, Penagos M: Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008 (in press).Google Scholar
  27. 27.
    Larché M: Peptide immunotherapy for allergic diseases. Allergy 2007, 62:325–331.PubMedCrossRefGoogle Scholar
  28. 28.
    Norman PS: Immunotherapy: 1999–2004. J Allergy Clin Immunol 2004, 113:1013–1023.PubMedCrossRefGoogle Scholar
  29. 29.
    Walker C, Zuany-Amorim C: New trends in immunotherapy to prevent atopic diseases. Trends Pharmacol Sci 2001, 22:84–90.PubMedCrossRefGoogle Scholar
  30. 30.
    von Garnier C, Astori M, Kettner A, et al.: Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol 2000, 30:1638–1645.CrossRefGoogle Scholar
  31. 31.
    Alexander C, Tarzi M, Larché M, Kay AB: The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005, 60:1269–1274.PubMedCrossRefGoogle Scholar
  32. 32.
    Tarzi M, Klunker S, Texier C, et al.: Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006, 36:465–474.PubMedCrossRefGoogle Scholar
  33. 33.
    Jutel M, Jaeger L, Suck R, et al.: Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005, 116:608–613.PubMedCrossRefGoogle Scholar
  34. 34.
    Esch R: Evaluation of allergen vaccine potency. Curr Allergy Asthma Rep 2006, 6:402–406.PubMedCrossRefGoogle Scholar
  35. 35.
    Jutel M, Cromwell O: Clinical results from vaccination with recombinant grass pollen allergens. Clin Dev Immunol 2006, 13:389–394.PubMedCrossRefGoogle Scholar
  36. 36.
    Gabler M, Scheiblhofer S, Kern K, et al.: Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006, 118:734–741.PubMedCrossRefGoogle Scholar
  37. 37.
    Kim N, Kwon SS, Lee J, et al.: Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy. Clin Mol Allergy 2006, 4:4.PubMedCrossRefGoogle Scholar
  38. 38.
    Behrmann J: Looking ahead at the potential benefits of biotechnology-derived allergen therapeutics. Clin Mol Allergy 2007, 5:3.PubMedCrossRefGoogle Scholar
  39. 39.
    Creticos PS, Schroeder JT, Hamilton RG, et al.: Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445–1455.PubMedCrossRefGoogle Scholar
  40. 40.
    Nayak AS, Tripathy I, Levitt D: Novel Amb a 1 CpG oligodeoxyribonucleotide conjugate ragweed vaccine administered to children. J Allergy Clin Immunol 2006, 117:S159.CrossRefGoogle Scholar
  41. 41.
    Francis JN, Durham SR: Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004, 4:543–548.PubMedCrossRefGoogle Scholar
  42. 42.
    Yazi D, Akkoc T, Yesil O, et al.: Treatment with Mycobacterium vaccae ameliorates airway histopathology in a murine model of asthma. Allergy Asthma Proc 2008, 29:67–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Arkwright PD, David TJ: Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001, 107:531–534.PubMedCrossRefGoogle Scholar
  44. 44.
    Berth-Jones J, Arkwright PD, Marasovic D, et al.: Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy 2006, 36:1115–1121.PubMedCrossRefGoogle Scholar
  45. 45.
    Camporota L, Corkhill A, Long H, et al.: The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 2003, 21:287–293.PubMedCrossRefGoogle Scholar
  46. 46.
    Shen H, Huang H, Wang J, et al.: Neonatal vaccination with bacillus Calmette-Guérin elicits long-term protection in mouse-allergic responses. Allergy 2008, 63:555–563.PubMedCrossRefGoogle Scholar
  47. 47.
    Linehan MF, Frank TL, Hazell ML, et al.: Is the prevalence of wheeze in children altered by neonatal BCG vaccination? J Allergy Clin Immunol 2007, 119:1079–1085.PubMedCrossRefGoogle Scholar
  48. 48.
    Shirtcliffe PM, Easthope SE, Weatherall M, Beasley R: Effect of repeated intradermal injections of heat-inactivated Mycobacterium bovis bacillus Calmette-Guérin in adult asthma. Clin Exp Allergy 2004, 34:207–212.PubMedCrossRefGoogle Scholar
  49. 49.
    Walker S, Monteil M, Phelan K, et al.: Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, 2:CD003559.Google Scholar
  50. 50.
    Kuehr J, Brauburger J, Zielen S, et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:274–280.PubMedCrossRefGoogle Scholar
  51. 51.
    Tari MG, Mancino M, Monti G: Efficacy of sublingual immunopathology in patients with rhinitis and asthma due to house dust mite. A double-blind study [in Spanish]. Allergol Immunopathol (Madr) 1990, 18:277–284.Google Scholar
  52. 52.
    Hirsch T, Sähn M, Leupold W: Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997, 8:21–27.PubMedCrossRefGoogle Scholar
  53. 53.
    Vourdas D, Syrigou E, Potamianou P, et al.: Double-blind placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998, 53:662–672.PubMedCrossRefGoogle Scholar
  54. 54.
    La Rosa M, Ranno C, André C, et al.: Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999, 104:267–270.CrossRefGoogle Scholar
  55. 55.
    Novembre E, Galli E, Landi F, et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851–857.PubMedCrossRefGoogle Scholar
  56. 56.
    Pajno GB, Morabito L, Barberio G, Parmiani S: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000, 55:842–849.PubMedCrossRefGoogle Scholar
  57. 57.
    Ozdemir C, Yazi D, Gocmen I, et al.: Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007, 18:508–515.PubMedCrossRefGoogle Scholar
  58. 58.
    Ippoliti F, De Santis W, Volterrani A, et al.: Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003, 14:216–221.PubMedCrossRefGoogle Scholar
  59. 59.
    Wüthrich B, Bucher CH, Jörg W, et al.: Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003, 13:145–148.PubMedGoogle Scholar
  60. 60.
    Bufe A, Ziegler-Kerbach E, Stoeckmann E, et al.: Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004, 59:498–504.PubMedCrossRefGoogle Scholar
  61. 61.
    Rolinck-Werninghaus C, Wolf H, Liebke C, et al.: A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285–1293.PubMedCrossRefGoogle Scholar
  62. 62.
    Niu CK, Chen WY, Huang JL, et al.: Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006, 100:1374–1383.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Noel Rodríguez-Pérez
    • 1
  • Martin Penagos
  • Jay M. Portnoy
  1. 1.Allergy ClinicTamaulipasMexico

Personalised recommendations